Dementia and Alzheimer Disease

As hospitalizations remain high throughout the COVID-19 pandemic, new data suggests that ICU hospitalization is associated with increased risk of Alzheimer disease and all-type dementia.

The assistant director of computational biology at Stanford University provided background on recent findings of two rare APOE missense variants and reduced risk of Alzheimer disease associated with them. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 29, 2022.

After an investigative report published in Science called to question years of research around the existence of an amyloid oligomer known as Aß*56, debates about the amyloid hypothesis have been reignited in the Alzheimer community.

The professor of psychiatry and cell biology at NYU Langone provided insight on the reaction to a new paper that challenges how traditional drug development has approached Alzheimer disease. [WATCH TIME: 4 minutes]

Get caught up on some of the latest news in Alzheimer disease and dementia, with data updates and expert insights, all in one place from the NeurologyLive® team.

Despite recent technological advancements, fewer participants underwent polysomnography and medical grade actigraphy, with minimal adoption of non-PSG electroencephalograms.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided context on the influence that genetics will have in drug development for Alzheimer disease in the coming years.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami detailed a new international initiative that expands on the genetic backgrounds of people of Hispanic and African ancestry. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

For amyloid positive cognitively unimpaired individuals, the best predicting compositive measure included gender, and changes in ADAS delayed recall, MMSE, SDMT, and Trailmaking Test B.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 22, 2022.

As previous literature has suggested a link between NAFLD and cognitive dysfunction, new findings showed that the disease was associated with a 38% higher rate of dementia.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared towards understanding genetic differences of underrepresented groups. [WATCH TIME: 6 minutes]

The double-blind, placebo-controlled, randomized trial will evaluate CT1812, a small molecule therapeutic designed to address the dual assault from α-synuclein and amyloid-ß oligomers in patients with dementia with Lewy bodies.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed non-APOE–related genetic correlations between different groups of individuals and Alzheimer disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Neurology News Network for the week ending July 16, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 15, 2022.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided insight on the outlook on genetics and gene-based therapies for Alzheimer disease. [WATCH TIME: 3 minutes]

In a meta-analysis spanning 10 studies of 1300 patients with Alzheimer disease, global cognition, as measured by the Mini-Mental State Examination or ADAS-Cog, was improved using noradrenergic drugs.

In comparison with controls, there were no significant differences in MRI volumes, amyloid-ß or tau accumulation, nor in most longitudinal measures among those with traumatic brain injury and/or PTSD.

The risk of developing Alzheimer disease and related dementias decreased gradually with increasing scores in a dose-response manner on a model geared toward identifying healthy lifestyle factors.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Neurology News Network for the week ending July 9, 2022. [WATCH TIME: 4 minutes]

Those with the common thyroid disorder displayed a more than 80% increased risk of dementia, with a more than 3-fold increase in the risk among those requiring hormone replacement therapy.